Revolution Medicines Inc (RVMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Revolution Medicines Inc (RVMD) Stock Forecast
Analysts expect Revolution Medicines (RVMD) to earn -$8.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $625.36M. Of 25 analysts, 24 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 25 ratings average 1.84, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 96% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 20.0% |
| Buy | 19 | 76.0% |
| Hold | 1 | 4.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 25
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 224.6%.
- Fiscal year ending Dec 31, 2026
- -$8.30
- EPS consensus, revenue $625.36M
- Fiscal year ending Dec 31, 2027
- -$3.10
- EPS consensus, revenue $2.03B
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$8.30 | -$9.84 to -$7.18 | 22 | $625.36M | $395.10M to $832.60M | 19 |
| Dec 31, 2027 | -$3.10 | -$9.91 to $2.49 | 23 | $2.03B | $682.20M to $3.37B | 23 |
Quarterly Estimates
The EPS consensus rises from -$1.87 for the quarter ending Dec 31, 2026 to -$0.81 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.87 | -$3.46 to -$0.85 | 25 | $227.96M | $43.73M to $528.36M | 23 |
| Mar 31, 2027 | -$0.81 | -$2.35 to $0.38 | 11 | $462.04M | $137.00M to $685.00M | 10 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 26 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 14 | 1 |
| Fiscal year ending Dec 31, 2027 | 12 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$9.56.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$8.30 | -$9.58 | -$9.62 | -$9.73 | -$9.56 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.10 | -$5.76 | -$5.72 | -$5.95 | -$6.60 | N/A |
| Quarter ending Mar 31, 2027 | -$0.81 | -$1.83 | -$1.84 | -$1.84 | -$1.90 | N/A |
Frequently Asked Questions About RVMD
What is the RVMD stock forecast?
Consensus analyst estimates put Revolution Medicines's EPS at -$8.30 for the fiscal year ending Dec 31, 2026, on revenue of $625.36M. The consensus rating from 25 analysts is Buy.
How do analysts rate RVMD stock?
Of 25 analysts covering Revolution Medicines, 5 rate it Strong Buy, 19 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RVMD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$8.30, with estimates from -$9.84 to -$7.18 from 22 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.10, with estimates from -$9.91 to $2.49 from 23 analysts.
What revenue do analysts expect from Revolution Medicines next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $625.36M, with estimates from $395.10M to $832.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.03B, with estimates from $682.20M to $3.37B.
How many analysts cover RVMD?
25 analysts rate Revolution Medicines stock, and 22 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RVMD pages: Overview, Earnings, Forecast, Financials, Competitors